EP0757697A4 - Verwendung von agentien, die die interzellülare wechselwirkung inhibieren, in der behandlung von viralen infektionen des atemweges - Google Patents

Verwendung von agentien, die die interzellülare wechselwirkung inhibieren, in der behandlung von viralen infektionen des atemweges

Info

Publication number
EP0757697A4
EP0757697A4 EP95916347A EP95916347A EP0757697A4 EP 0757697 A4 EP0757697 A4 EP 0757697A4 EP 95916347 A EP95916347 A EP 95916347A EP 95916347 A EP95916347 A EP 95916347A EP 0757697 A4 EP0757697 A4 EP 0757697A4
Authority
EP
European Patent Office
Prior art keywords
breath
viral
infection
treatment
agents inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95916347A
Other languages
English (en)
French (fr)
Other versions
EP0757697A1 (de
Inventor
Craig D Wegner
Ernest L Raymond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharmaceuticals Inc
Publication of EP0757697A1 publication Critical patent/EP0757697A1/de
Publication of EP0757697A4 publication Critical patent/EP0757697A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP95916347A 1994-04-12 1995-04-12 Verwendung von agentien, die die interzellülare wechselwirkung inhibieren, in der behandlung von viralen infektionen des atemweges Withdrawn EP0757697A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22599794A 1994-04-12 1994-04-12
PCT/US1995/004519 WO1995027736A1 (en) 1994-04-12 1995-04-12 Use of agents which block intercellular adhesion molecule/receptor interaction in the treatment of respiratory viral infection
US225997 1999-01-05

Publications (2)

Publication Number Publication Date
EP0757697A1 EP0757697A1 (de) 1997-02-12
EP0757697A4 true EP0757697A4 (de) 2000-05-17

Family

ID=22847133

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95916347A Withdrawn EP0757697A4 (de) 1994-04-12 1995-04-12 Verwendung von agentien, die die interzellülare wechselwirkung inhibieren, in der behandlung von viralen infektionen des atemweges

Country Status (4)

Country Link
EP (1) EP0757697A4 (de)
JP (1) JPH09512252A (de)
CA (1) CA2187360A1 (de)
WO (1) WO1995027736A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362531B1 (de) 1988-09-01 1999-11-10 Bayer Corporation Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US5817515A (en) * 1993-12-23 1998-10-06 Icos Corporation Human B2 integrin alpha subunit antibodies
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
JP2007535654A (ja) * 2003-04-23 2007-12-06 ハンサ メディカル アクチボラゲット 抗連鎖球菌物質の確認方法、及び連鎖球菌感染症治療のためのその使用
US12447166B2 (en) * 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
US12594285B2 (en) 2016-02-25 2026-04-07 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
EP3419629A4 (de) 2016-02-25 2019-10-30 Applied Biological Laboratories, Inc. Zusammensetzungen und verfahren zum schutz gegen luftbürtige pathogene und reizmittel

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289949A2 (de) * 1987-05-04 1988-11-09 Dana Farber Cancer Institute Interzellulare Adhäsions-Moleküle und deren Bindungsliganden
EP0314863A2 (de) * 1987-11-02 1989-05-10 Baylor College Of Medicine Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen
EP0391088A2 (de) * 1989-03-16 1990-10-10 Center For Blood Research Laboratories, Inc. Verwendung von funkionellen Derivaten des Interzellulär-Adhäsions-Moleküls ICAM-1 in einer Antivirus-Therapie
WO1993006842A1 (en) * 1991-10-02 1993-04-15 Boehringer Ingelheim Pharmaceuticals, Inc. Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma
US5235049A (en) * 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0289949A2 (de) * 1987-05-04 1988-11-09 Dana Farber Cancer Institute Interzellulare Adhäsions-Moleküle und deren Bindungsliganden
EP0314863A2 (de) * 1987-11-02 1989-05-10 Baylor College Of Medicine Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen
US5235049A (en) * 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
EP0391088A2 (de) * 1989-03-16 1990-10-10 Center For Blood Research Laboratories, Inc. Verwendung von funkionellen Derivaten des Interzellulär-Adhäsions-Moleküls ICAM-1 in einer Antivirus-Therapie
WO1993006842A1 (en) * 1991-10-02 1993-04-15 Boehringer Ingelheim Pharmaceuticals, Inc. Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KAPELANSKI D P ET AL: "Lung reperfusion injury is reduced by inhibiting a CD18-dependent mechanism.", JOURNAL OF HEART AND LUNG TRANSPLANTATION, (1993 MAR-APR) 12 (2) 294-306;DISCUSSION 306-7., XP000881402 *
ROTHLEIN R ET AL: "TREATMENT OF INFLAMMATION WITH ANTI-ICAM-1", RESEARCH IN IMMUNOLOGY,FR,PARIS, vol. 144, no. 9, 1 January 1993 (1993-01-01), pages 735 - 739,754-76, XP000575989 *
See also references of WO9527736A1 *
WEGNER C D ET AL: "Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma.", SCIENCE, (1990 JAN 26) 247 (4941) 456-9., XP000872999 *
WEGNER, CRAIG D: "Adhesion molecules in allergy", PROG. ALLERGY CLIN. IMMUNOL., PROC. INT. CONGR. ALLERGOL. CLIN. IMMUNOL., 15TH (1995), MEETING DATE 1994, 13-18. EDITOR(S): JOHANSSON, STIG G. O. PUBLISHER: HOGREFE & HUBER, SEATTLE, WASH., XP000881448 *

Also Published As

Publication number Publication date
JPH09512252A (ja) 1997-12-09
CA2187360A1 (en) 1995-10-19
WO1995027736A1 (en) 1995-10-19
EP0757697A1 (de) 1997-02-12

Similar Documents

Publication Publication Date Title
ATE110556T1 (de) Verbesserungen bei der behandlung von zähnen.
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE69903543D1 (de) Formulierungen zur behandlung von magen-speiseröhren reflux
DE69830660D1 (de) Behandlung von atemstillstand im schlaf
DE69915087D1 (de) Behandlung von textilien
DE69500089D1 (de) Behandlung von Geflügel
ATE300597T1 (de) Behandlung von geweben
DE69718731D1 (de) Kombinationstherapie für die Behandlung von Psychosen
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
EP1001782A4 (de) 5,6-HETEROARYL-DIPYRIDO (2-3-b:3',2'-f) AZEPINE UND DEREN VERWENDUNG ZUR PROPHYLAXE UND BEHANDLUNG VON HIV-INFEKTIONEN
DE69530860D1 (de) Behandlung der entzündung des sehnervs
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
DE69912609D1 (de) Behandlung von in der luft enthaltenen mikroorganismen
ATE292975T1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
DE69833297D1 (de) Substituierte Pyridylmethylpiperazin- und piperidinderivate, deren Herstellung und deren Verwendung in der Behandlung von Erkrankungen des Zentralnervensystems (ZNS)
FI963752L (fi) Meesan lämpökäsittely
DE69110713D1 (de) 7-Oxabicycloheptan-imidazol-prostaglandin-Analoge, verwendbar bei der Behandlung von thrombotischen und vasospastischen Erkrankungen.
DE3850433D1 (de) Allergiebehandlung und Zusammensetzung dafür.
DE69012627D1 (de) Behandlung von Aluminiumlegierungen.
DE69534632T2 (de) Clotrimazol-Metaboliten bei der Behandlung von Sichelzellenkrankheit
DE69518438D1 (de) Behandlung von übereregten nervenzellenfunktionen
ZA923935B (en) New 2-amino-5-cyano-1,4-dihydropyridines,processes for their preparation and their use in medicaments

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000329

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20000825

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011108